TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis
Brief Summary: This study was conducted to explore a new therapy for anemia in participants with end stage renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin (which contains iron) is important for the transport of oxygen in your blood. The purpose of this study was to evaluate if roxadustat is effective and safe in the maintenance treatment of anemia in ESRD participants on stable dialysis. Roxadustat was compared to epoetin alfa and darbepoetin alfa, commercially available medicines for treatment of anemia.


Options:
A: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Iron | Arm Label: ESA (Erythropoiesis Stimulating Agent) treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa, Drug: Darbepoetin alfa, Drug: Iron | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment | Intervention Type: DRUG; Name: Iron; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment, Roxadustat
B: Arm Label: Participants receiving Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Participants receiving Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Participants receiving Daprodustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Participants receiving Epoetin alfa
C: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Healthy Lifestyle Behaviors in Primary Schoolchildren: Evaluation and Implementation of an Online Video Intervention for Parents
Brief Summary: 1. Development of a method for parents of primary schoolchildren to teach parents parenting skills to obtain health gain in the family through videos and online feedback.
2. Effect- and procesevaluation of this methodology.
3. Development of an implementation guide together with VIGEZ as primary partner and in association with partner organisations on the field.


Options:
A: Arm Label: Family Spirit Nurture (FSN); Type: EXPERIMENTAL; Interventions: Behavioral: Family Spirit Nurture (FSN), Other: Optimized Standard Care (OSC) | Arm Label: Control Program; Type: OTHER; Interventions: Other: Injury Prevention Education (IPE), Other: Optimized Standard Care (OSC) | Intervention Type: BEHAVIORAL; Name: Family Spirit Nurture (FSN); Assigned to Arm(s): Family Spirit Nurture (FSN) | Intervention Type: OTHER; Name: Injury Prevention Education (IPE); Assigned to Arm(s): Control Program | Intervention Type: OTHER; Name: Optimized Standard Care (OSC); Assigned to Arm(s): Control Program, Family Spirit Nurture (FSN)
B: Arm Label: Optimisation + HENRY; Type: EXPERIMENTAL; Interventions: Behavioral: Optimisation + HENRY | Arm Label: HENRY as standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HENRY as standard | Intervention Type: BEHAVIORAL; Name: Optimisation + HENRY; Assigned to Arm(s): Optimisation + HENRY | Intervention Type: BEHAVIORAL; Name: HENRY as standard; Assigned to Arm(s): HENRY as standard
C: Arm Label: waitlist control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Movie Models | Intervention Type: BEHAVIORAL; Name: Movie Models; Assigned to Arm(s): intervention group
D: Intervention Type: BEHAVIORAL; Name: attitude change; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: adiposity prevention program; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Filipinos Fit and Trim Weight Loss for Diabetes Prevention Program
Brief Summary: Filipino Americans (FA) are the second largest (3.4 million) Asian group in the US. and have one of the highest prevalences of obesity and type 2 diabetes mellitus compared to non-Hispanic whites, African Americans and Hispanics. However, FA have been underrepresented in health related research, particularly in diabetes prevention. This proposed pilot study is the first clinical trial to assess preliminary estimates of the short-term effect of the novel social networking diabetes prevention program lifestyle intervention for this high-risk population.


Options:
A: Arm Label: Low carb - App-based group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight maintenance intervention | Arm Label: Low carb - Newsletter-based group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight maintenance intervention | Arm Label: Low fat - App-based group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight maintenance intervention | Arm Label: Low fat - Newsletter-based group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight maintenance intervention | Intervention Type: BEHAVIORAL; Name: Weight maintenance intervention; Assigned to Arm(s): Low carb - App-based group, Low carb - Newsletter-based group, Low fat - App-based group, Low fat - Newsletter-based group
B: Arm Label: Fit and Trim group; Type: EXPERIMENTAL; Interventions: Behavioral: Filipinos Fit and Trim Weight Loss Program | Arm Label: Pedometer only group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Filipinos Fit and Trim Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Filipinos Fit and Trim Weight Loss Program; Assigned to Arm(s): Fit and Trim group, Pedometer only group
C: Arm Label: W82GO; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: W82GO | Arm Label: Smartphone; Type: EXPERIMENTAL; Interventions: Device: smartphone application | Intervention Type: BEHAVIORAL; Name: W82GO; Assigned to Arm(s): W82GO | Intervention Type: DEVICE; Name: smartphone application; Assigned to Arm(s): Smartphone
D: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: APP + health advice | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: health advice | Intervention Type: BEHAVIORAL; Name: APP + health advice; Assigned to Arm(s): intervention group | Intervention Type: BEHAVIORAL; Name: health advice; Assigned to Arm(s): control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Type 2 Diabetic Patients; EFFECT II
Brief Summary: This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with Type 2 diabetes with fatty liver (\>5.5% as measured with magnetic resonance imaging (MRI))


Options:
A: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
B: Arm Label: TREATED GROUP; Type: EXPERIMENTAL; Interventions: Drug: Hydroxytyrosol plus Vitamin E | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxytyrosol plus Vitamin E; Assigned to Arm(s): TREATED GROUP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP
C: Arm Label: Prebiotic Fibre; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotic fibre, Behavioral: Weight Loss | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Behavioral: Weight Loss | Arm Label: Weight Loss; Type: OTHER; Interventions: Behavioral: Weight Loss | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic fibre; Assigned to Arm(s): Prebiotic Fibre | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Placebo, Prebiotic Fibre, Weight Loss
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Omega-3 carboxylic acids 4g / day; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 carboxylic acids | Arm Label: Dapagliflozin, 10mg / day; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin | Arm Label: Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 carboxylic acids, Drug: Dapagliflozin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Omega-3 carboxylic acids; Assigned to Arm(s): Omega-3 carboxylic acids 4g / day, Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin, 10mg / day, Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Brief Summary: Liprotamase powder is a non-porcine, soluble and stable mixture of three digestive enzymes including lipase, protease, and amylase. The purpose of the present study is to provide additional efficacy and safety data compared to approved, porcine-derived, enterically-coated and encapsulated pancreatic enzyme replacement therapy. The primary efficacy endpoint of the study will be comparative efficacy measured as the change in the coefficient of fat absorption (CFA) in Cystic Fibrosis patients with exocrine pancreatic insufficiency (EPI).

Liprotamase is stable in stomach and digestive fluids allowing administration in a variety of convenient formulations and with a number of foods without enteric coating.


Options:
A: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: porcine (pig) PERT; Type: ACTIVE_COMPARATOR; Interventions: Drug: porcine (pig) PERT | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: porcine (pig) PERT; Assigned to Arm(s): porcine (pig) PERT
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pancrelipase Delayed Release | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pancrelipase Delayed Release; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): B
C: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Cystic Fibrosis in 1st 3 months of life; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-level Communications and Access Strategies to Improve the Food Environment:B'More Healthy: Retailer Rewards (BHRR)
Brief Summary: The overarching goal of B'More Healthy Retail Rewards (BHRR) is to develop, implement, and evaluate a pilot multi-level communications and pricing intervention to improve access to and consumption of healthy foods in low-income areas of Baltimore City, Maryland. BHRR has three primary aims: (1) to conduct formative research with representatives of multiple levels of the Baltimore food environment (i.e., local wholesalers, retail food store owners, and consumers) in order to select key foods for promotion, and determine appropriate communications and healthy food price reduction strategies, (2) to pilot the multi-level program with 2 local wholesale stores, and 24 small corner stores and their customers, and assess program implementation through detailed process evaluation, and (3) to assess impact of multilevel health communications and pricing strategies, combined and separately, on consumer dietary patterns and food source use, food purchasing behaviors, psychosocial variables, food security, and individual weight and height.


Options:
A: Arm Label: Consumer Support; Type: EXPERIMENTAL; Interventions: Other: Control condition | Arm Label: Consumer Support with Effectiveness Info; Type: EXPERIMENTAL; Interventions: Other: Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages | Intervention Type: OTHER; Name: Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages; Assigned to Arm(s): Consumer Support with Effectiveness Info | Intervention Type: OTHER; Name: Control condition; Assigned to Arm(s): Consumer Support
B: Arm Label: Water; Type: EXPERIMENTAL; Interventions: Other: Water | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Education | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water | Intervention Type: OTHER; Name: Education; Assigned to Arm(s): Control
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Grab a Cup, Fill it Up | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Grab a Cup, Fill it Up; Assigned to Arm(s): Intervention
D: Arm Label: Communications; Type: EXPERIMENTAL; Interventions: Other: Communications | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pricing; Type: EXPERIMENTAL; Interventions: Other: Pricing | Arm Label: Combined (Communications & Pricing); Type: EXPERIMENTAL; Interventions: Other: Combined (Communications & Pricing) | Intervention Type: OTHER; Name: Communications; Assigned to Arm(s): Communications | Intervention Type: OTHER; Name: Pricing; Assigned to Arm(s): Pricing | Intervention Type: OTHER; Name: Combined (Communications & Pricing); Assigned to Arm(s): Combined (Communications & Pricing)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Interactive Web-Based Education and Interactive Voice Response (Automated Follow-up) Programs on CPAP Adherence for the Treatment of Obstructive Sleep Apnea
Brief Summary: The primary and well-known challenge with continuous positive airway pressure (CPAP) is the incomplete adherence of patients to this therapy. Successfully improving CPAP use is likely through emphasizing patient education regarding the risks associated with obstructive sleep apnea (OSA), potential benefits of therapy, teaching techniques to acclimate to CPAP, and providing a system of accountability through a follow-up process. With the changing landscape of healthcare reimbursement which emphasizes achieving positive clinical outcomes, discovering more automated and self-directed methods of educating and follow-up is needed.

The investigators plan to investigate the impact of adjunct Web education and automated follow-up on CPAP use and other measurements of patient engagement. The specific aims of this pilot study are as follows:

1. Assess impact of Telemedicine mechanisms on CPAP use 3 months after initiating therapy in comparison to usual standard of care.
2. Assess impact of Telemedicine mechanisms on functional outcomes and parameters of healthcare utilization at 3 months after initiation of therapy in comparison to usual standard of care.


Options:
A: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
B: Arm Label: Traditional; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine Education Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Education | Arm Label: Telemedicine IVR Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: IVR | Arm Label: Telemedicine Both Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Education, Behavioral: IVR | Intervention Type: BEHAVIORAL; Name: Telemedicine Education; Assigned to Arm(s): Telemedicine Both Pathway, Telemedicine Education Pathway | Intervention Type: BEHAVIORAL; Name: IVR; Assigned to Arm(s): Telemedicine Both Pathway, Telemedicine IVR Pathway
C: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
D: Intervention Type: BEHAVIORAL; Name: Targeted parental instruction for positive lifestyle change with follow-up calls.; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis
Brief Summary: The purpose of this study is to assess the efficacy of a low and high dose of a budesonide effervescent tablet and oral viscous budesonide suspension vs. placebo for the induction treatment of active eosinophilic esophagitis.


Options:
A: Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: mepolizumab; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: QAX576 placebo | Arm Label: QAX576; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAX576 | Intervention Type: DRUG; Name: QAX576 placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: QAX576; Assigned to Arm(s): QAX576
D: Arm Label: Low dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: low dose budesonide tablet | Arm Label: High dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide tablet | Arm Label: High dose budesonide suspension; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide suspension | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: low dose budesonide tablet; Assigned to Arm(s): Low dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide tablet; Assigned to Arm(s): High dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide suspension; Assigned to Arm(s): High dose budesonide suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Grab a Cup, Fill it up! An Intervention to Promote Convenience of Drinking Water and Increase Student Water Consumption During School Lunch.
Brief Summary: This study, randomized, delivered, and analyzed at the school level, evaluated the effect of simple, structural changes to school lunch rooms to make drinking water easier for students during lunch time. Half of the schools received posters promoting drinking water and installed cup dispensers stocked with cups next to lunchroom water fountains, while the other half received no intervention. The intervention outcomes were average water consumption and the proportion of students in the lunchroom who opted to drink water, as well as the proportion of students with sugary drinks at lunch. No identifying information on individual children was collected.


Options:
A: Arm Label: Calorie Label; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: Warning Label; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: Warning Label with Graphics; Type: EXPERIMENTAL; Interventions: Other: Label Condition | Arm Label: No label; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Label Condition; Assigned to Arm(s): Calorie Label, Warning Label, Warning Label with Graphics
B: Arm Label: reducing beverages and sugar and increase physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle | Arm Label: control -no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: lifestyle; Assigned to Arm(s): reducing beverages and sugar and increase physical activity
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Grab a Cup, Fill it Up | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Grab a Cup, Fill it Up; Assigned to Arm(s): Intervention
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: KAN-DO | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: KAN-DO | Intervention Type: BEHAVIORAL; Name: KAN-DO; Assigned to Arm(s): 1, 2

Answer: C